21 March 2024
Direct Oral Anticoagulants (DOACs) have largely overtaken vitamin K antagonists and the heparins as the preferred anticoagulant for an expanding number of indications with similar or even superior safety and efficacy. The limits of its utility are also being tested on many previously forbidden fronts. We now have better clarity in our knowledge and understanding of its safety and efficacy in sub-populations such as the renally impaired, extremes of weight, cancer patients and patients with thrombosis in unusual sites. Many such sub-population have an unmet need in anticoagulant options. This lecture will discuss the intricacies of DOAC use outside of mainstream populations and how we can best navigate anticoagulating these individuals with or without the DOACs.
After the lecture, the participants will be able to gain an understanding on:
Click here for more lecture details.
To register (internet access is required), scan the QR code or click on the web link. Registration closes on 28 February 2024, Wednesday.
Upon registration, participants agreed to PGAHI Terms & Conditions. Kindly note that PGAHI reserves the right of final decision on lecture registration.
Lecture Details
Date:
21 March 2024, Thursday
Timing:
6.30 pm - 7.30 pm
Duration:
60 minutes
Fees:
Complimentary
Platform:
Zoom Cloud Meetings
Registration Closing Date:
28 February 2024, Wednesday
Target Audience:
Pharmacists
(Zoom Capacity: 500
This lecture will be conducted via Zoom Cloud Meetings app. For ease of accessing the lecture, please download/update Zoom Cloud Meetings app. Details of the lecture meeting link will be sent to the successful registrants nearer the lecture date.)
